TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1526089
Drug: Nizatidine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine (both doses)
Study: 31765956
Drug: Uninoculated plants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uninoculated plants under 200 mg kg-1 Cr stress
Study: 25487082
Drug: Elosulfase alfa
Normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Elosulfase alfa 2.0 mg/kg administered every other week
Study: 25559914
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose exercise (150 min/week)
Study: 25559914
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose exercise (300 min/week)
Study: 21619917
Drug: Ethanolic extract
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanolic extract of Tulsi leaves (300 mg capsules)
Study: 14626181
Drug: Composite Salvia
Normalized name: Salvia sclarea seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite Salvia Injection (CSI) plus Western Medicine (WM)
Study: 12080674
Drug: Western Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western Medicine (WM)
Study: 11099285
Drug: Non-directive counselling
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-directive counselling and Cognitive-behaviour therapy
Study: 29727013
Drug: Everolimus, target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus, target Cmin range of 5-7 ng/mL initially and 5-15 ng/mL for inadequate response.
Study: 21920335
Drug: Atorvastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin monotherapy or atorvastatin-based combination therapies
Study: 18312050
Drug: Methylphenidate transdermal
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate transdermal system patch (10-30 mg, 9-hour wear time)
Study: 18312050
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate capsule (18-54 mg)
Study: 25335329
Drug: Shugan Jiangu
Normalized name: Jiang Huang (Curcuma Longa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shugan Jiangu Recipe (SJR), 6 g twice daily for 6 months
Study: 10406689
Drug: Heparin-coated stents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated stents
Study: 11996329
Drug: Capsule formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule formulation of R115777 (300 or 400 mg)
Study: 9702468
Drug: Miglitol (BAY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol (BAY m 1099), 100 mg tds
Study: 2685532
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g plain aspirin (swallowed)
Study: 800971
Drug: 0.25% desoxymethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% desoxymethasone ointment
Study: 6370438
Drug: 0.05% fluocinonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% fluocinonide ointment
Study: 27297851
Drug: Levosimendan (0.05-0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.05-0.2 μg/[kg min])
Study: 24053564
Drug: placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (two tablets twice daily)
Study: 12412834
Drug: Sustained-release bupropion
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release bupropion (300 mg/day)
Study: 12439626
Drug: Nefazodone (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (450 mg/day)
Study: 12412834
Drug: Oral delta9-THC
Normalized name: .DELTA.1-THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral delta9-THC (10, 20, 30 mg PO)
Study: 2403818
Drug: 7‐3‐7 regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7‐3‐7 regimen (same drugs intensified with etoposide 75 mg/m2/d IV days 1-7)
Study: 30904553
Drug: Simultaneous implant
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous implant and CTG placement (test group)
Study: 16424413
Drug: Cilomilast, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilomilast, 15 mg bid
Study: 28877913
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg/d
Study: 11355925
Drug: Intensified chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified chemotherapy including high-dose Ara-C
Study: 9397386
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 50 micrograms/day and NETA (170 micrograms/day) given continuously
Study: 9397386
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 50 micrograms/day and NETA (350 micrograms/day) given continuously
Study: 9397386
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 50 micrograms/day and NETA given sequentially (last 14 days of each treatment cycle)
Study: 2492744
Drug: Carnitine-free total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnitine-free total parenteral nutrition (TPN)
Study: 3148789
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (12 mg/kg.day)
Study: 23452524
Drug: Standard postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative analgesic methods (applied to all patients).
Study: 17885551
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor ramipril
Study: 8908384
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for ACE inhibitor and Vitamin E
Study: 27338216
Drug: Emergency Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency Medicine
Study: 7996346
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered methylprednisolone, 30 mg/kg per day for 7 days (n = 19)
Study: 7996346
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered methylprednisolone, 50 mg/kg per day for 7 days (n = 19)
Study: 3281399
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg, suppositories, 3 times a day for 3 days)
Study: 1555873
Drug: Heparin-coated extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated extracorporeal circuit (Carmeda)
Study: 1555873
Drug: Non-heparin-coated extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-heparin-coated extracorporeal circuit (Scimed)
Study: 638969
Drug: Intralesional BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional BCG therapy
Study: 30826774
Drug: ianalumab 10
Normalized name: Ianalumab
DrugBank: Ianalumab (DB16666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ianalumab 10 mg/kg
Study: 26100253
Drug: Bevacizumab (BEV)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (BEV) combined with standard chemotherapy
Study: 24094982
Drug: Perioperative low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative low dose vaginal oestrogens
Study: 19847908
Drug: Rituximab (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1,000 mg intravenous infusions every 24 weeks for 96 weeks)
Study: 3276283
Drug: mCPP administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mCPP administration after clomipramine treatment
Study: 3276283
Drug: mCPP administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mCPP administration before clomipramine treatment
Study: 30671976
Drug: Curcumin (1440
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (1440 mg/day) for 6 months
Study: 21617168
Drug: A1AT replacement
Normalized name: Dcr-a1at
DrugBank: Belcesiran (DB18226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A1AT replacement therapy
Study: 7503196
Drug: 2% clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% clindamycin vaginal cream
Study: 28615379
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNS-PL) containing 250 μg I, 20 g/d, 118 kcal
Study: 21810005
Drug: Olopatadine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine 5 mg twice daily (drug‐change group)
Study: 21810005
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg once daily (initial treatment)
Study: 21118744
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of venlafaxine extended-release 75-mg capsules (fasting)
Study: 21118744
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of venlafaxine extended-release 75-mg capsules (fasting)
Study: 21118744
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of venlafaxine extended-release 75-mg capsules (fed)
Study: 21118744
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (fasting and fed)
Study: 10410404
Drug: Isobaric tetracaine
Normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isobaric tetracaine (2.0 mL of 0.5% tetracaine in cerebrospinal fluid)
Study: 2188926
Drug: aclacinomycin-A (ACM-A,
Approvals — FDA: no, EMA: no, PMDA: no
Description: aclacinomycin-A (ACM-A, 100 mg/m2 or 85 mg/m2, every 3 weeks)
Study: 23377392
Drug: Efinaconazole 10%
Normalized name: EFINACONAZOLE 10% SOLN,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efinaconazole 10% solution (with or without semiocclusion)
Study: 23377392
Drug: Efinaconazole 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efinaconazole 5% solution
Study: 19534587
Drug: Sodium tanshinone
Normalized name: Tanshinone I
DrugBank: Tanshinone I (DB16886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium tanshinone IIA sulfonate (STS) 60 mg day(-1) injections for 13 days
Study: 19534587
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections for 13 days
Study: 15375791
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of adiponectin with insulin sensitivity
Study: 24866597
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both methods
Study: 9505987
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg venlafaxine tablet
Study: 9505987
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg venlafaxine tablet with food
Study: 9505987
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg venlafaxine solution
Study: 2036242
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus radiotherapy (total nodal or involved field irradiation)
Study: 30088663
Drug: ACT-246475 1
Normalized name: ACT-246475
DrugBank: Selatogrel (DB15163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-246475 1 mg
Study: 30088663
Drug: ACT-246475 2
Normalized name: sodium fluoride 0.2 MG/ML [ACT Fluoride Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-246475 2 mg
Study: 30088663
Drug: ACT-246475 4
Normalized name: ACT-246475
DrugBank: Selatogrel (DB15163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-246475 4 mg
Study: 30088663
Drug: ACT-246475 8
Normalized name: ACT-246475
DrugBank: Selatogrel (DB15163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-246475 8 mg
Study: 1833834
Drug: Isradipine 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 5.0 mg twice daily
Study: 6126425
Drug: PCPL injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCPL injections
Study: 17766093
Drug: Levetiracetam (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (1500 mg/day)
Study: 9853771
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ursodeoxycholic acid and S-adenosylmethionine
Study: 7893582
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg daily for 2 weeks)
Study: 2735626
Drug: Zidovudine, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine, 250 mg orally every 4 hours
Study: 2735626
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (including zidovudine and placebo)
Study: 31788741
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy (VMP)
Study: 28129949
Drug: SMS text
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS text message intervention (daily reminders to monitor RMC)
Study: 26596540
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy for chest pain (CBT‐CP)
Study: 11120521
Drug: Pregestational diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregestational diabetes mellitus requiring insulin therapy
Study: 8317684
Drug: ketamine-racemat 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine-racemat 2 mg/kg
Study: 3987645
Drug: Cimetidine 1200
Normalized name: cimetidine 1200 mg-0.9%/500 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1200 mg/day
Study: 3743626
Drug: Digoxin 0.75
Normalized name: digoxin 0.75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.75 mg i.v. with cimetidine
Study: 31971474
Drug: Local heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local heat therapy (HT)
Study: 10542928
Drug: Topical AMETOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical AMETOP gel
Study: 10542928
Drug: Topical intranasal
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical intranasal cocaine (administered to all groups)
Study: 2358837
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with cyclophosphamide 4.5 to 5.25 g/m2, etoposide 750 to 1,200 mg/m2, and cisplatin 120 to 180 mg/m2 (CVP)
Study: 2358837
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with cyclophosphamide, etoposide, and cisplatin
Study: 778990
Drug: Floctafenine 200
Normalized name: floctafenine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Floctafenine 200 mg four times a day
Study: 25923818
Drug: Ultrasound-guided unilateral
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided unilateral TAP block with 20 mL 7.5 mg/mL ropivacaine
Study: 21586838
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (0.5 mg in 0.05 ml) monthly for 3 months
Study: 21586838
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (1.25 mg in 0.05 ml) monthly for 3 months
Study: 10731382
Drug: Normal daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal daily physical activity (Group 2, n = 64)
Study: 9042560
Drug: Enoxaparin 40mg
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40mg once daily for 21 days
Study: 9042560
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 21 days
Study: 1331558
Drug: Droperidol 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.25 mg.kg‐1 and fentanyl 5 micrograms.kg‐1 (group N)
Study: 3901663
Drug: 2-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose regimen of acetylsalicylic acid
Study: 3901663
Drug: 3-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose regimen of acetylsalicylic acid
Study: 26727506
Drug: High-dose trans-resveratrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose trans-resveratrol (450 mg/d)
Study: 24183737
Drug: Preoperative dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative dose of antibiotic (1g of amoxicillin) followed by a 3-day postoperative course.
Study: 12971031
Drug: Levofloxacin administered
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin administered with juice and cereal without milk
Study: 11039508
Drug: Ifosfamide (IFX)
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide (IFX) 2,000 mg/m2 IV infusion days 1 to 3; 2-mercaptoethanesulfonic acid sodium salt (mesna) 400 mg/m2 IV bolus H 0 and 4, 800 mg/m2 by mouth H 8, days 1 to 3; Vinorelbine (VNB) 25 mg/m2 IV infusion days 1 and 8; Cisplatin (CDDP) 75 mg/m2 IV day 3, repeated every 28 days for a total of three courses
Study: 30419961
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of conventional medicine and Traditional Chinese Medicine (TCM), administered twice daily for 28 days.
Study: 30419961
Drug: Conventional medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medicine alone (control group).
Study: 26880794
Drug: 0.1 mg/kg midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg midazolam
Study: 26880794
Drug: 1 mg/kg ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg ketamine
Study: 23019943
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy combined with Kanglaite Injection (KI) at 100 mL/d for 21 days, two cycles with one week interval.
Study: 20430262
Drug: Inhaled treprostinil
Normalized name: treprostinil Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled treprostinil (up to 54 mug) 4 times daily
Study: 8652332
Drug: MgSO4 60
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MgSO4 60 mg kg‐1 at recovery from vecuronium block to a TOF ratio of 0.7
Study: 6354282
Drug: Prednisolone (200‐300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (200‐300 mg over 48‐72 h)
Study: 18180279
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml triamcinolonacetonide (TCA)
Study: 15483019
Drug: Remaining group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remaining group (not specified treatment)
Study: 15483019
Drug: Cisplatin monotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin monotherapy (3 postoperative courses)
Study: 26302900
Drug: Waitlist control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist control group (treatment as usual for eight weeks)
Study: 18081357
Drug: Torasemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide (20 mg IV and 20 mg orally)
Study: 18081357
Drug: Furosemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (40 mg IV and 80 mg orally)
Study: 10480767
Drug: human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: human insulin 30/70
Study: 11575978
Drug: Ximelagatran 8
Normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran 8 mg twice daily
Study: 11575978
Drug: Ximelagatran 12
Normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran 12 mg twice daily
Study: 11575978
Drug: Ximelagatran 18
Normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran 18 mg twice daily
Study: 2740834
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CH and Triton X‐100
Study: 28754483
Drug: Olaparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (300 mg in two 150 mg tablets, twice daily)
Study: 19641893
Drug: Prehospital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehospital treatment and emergency management of pediatric trauma patients
Study: 7825247
Drug: Multiple cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple cytotoxic drug regimens
Study: 16648513
Drug: Adjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant systemic therapy
Study: 21199608
Drug: Distributed constraint-induced
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distributed constraint-induced therapy (dCIT)
Study: 1861872
Drug: Desipramine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (mean dose, 201 mg/day)
Study: 31100237
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) in WW group
Study: 25198030
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with a 5 grass pollen mixture
Study: 31272379
Drug: i-gel™
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel™
Study: 11823078
Drug: Trimetazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (20 mg) + Heparin (5,000 IU 10 min before exercise, followed by 1,000 IU/h)
Study: 11823078
Drug: Trimetazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (20 mg) + Saline (10 ml 10 min before exercise)
Study: 11823078
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Heparin (5,000 IU 10 min before exercise, followed by 1,000 IU/h)